|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Garcia-Murillas I, Schiavon G, Weigelt B,
Ng C, Hrebien S, Cutts RJ, Cheang M, Osin P, Nerurkar A, Kozarewa
I, et al: Mutation tracking in circulating tumor DNA predicts
relapse in early breast cancer. Sci Transl Med. 7:302ra1332015.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Im NK, Jang WJ, Jeong CH and Jeong GS:
Delphinidin suppresses PMA-induced MMP-9 expression by blocking the
NF-κB activation through MAPK signaling pathways in MCF-7 human
breast carcinoma cells. J Med Food. 17:855–861. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Shalaby MA, Nounou HA, Ms A, O A, Azzam N
and Saeed HM: Associations between single nucleotide polymorphisms
of COX-2 and MMP-2 genes and colorectal cancer susceptibility in
the Saudi population. Asian Pac J Cancer Prev. 15:4989–4994. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zhou R, Xu L, Ye M, Liao M, Du H and Chen
H: Formononetin inhibits migration and invasion of MDA-MB-231 and
4T1 breast cancer cells by suppressing MMP-2 and MMP-9 through
PI3K/AKT signaling pathways. Horm Metab Res. 46:753–760. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Chia CY, Kumari U and Casey PJ: Breast
cancer cell invasion mediated by Gα12 signaling involves expression
of interleukins-6 and −8, and matrix metalloproteinase-2. J Mol
Signal. 9:62014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Stoeltzing O, Ahmad SA, Liu W, McCarty MF,
Wey JS, Parikh AA, Fan F, Reinmuth N, Kawaguchi M, Bucana CD, et
al: Angiopoietin-1 inhibits vascular permeability, angiogenesis,
and growth of hepatic colon cancer tumors. Cancer Res.
63:3370–3377. 2003.PubMed/NCBI
|
|
8
|
Zhang W, Wang F, Xu P, Miao C, Zeng X, Cui
X, Lu C, Xie H, Yin H, Chen F, et al: Perfluorooctanoic acid
stimulates breast cancer cells invasion and up-regulates matrix
metalloproteinase-2/-9 expression mediated by activating NF-κB.
Toxicol Lett. 229:118–125. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Iochmann S, Bléchet C, Chabot V, Saulnier
A, Amini A, Gaud G, Gruel Y and Reverdiau P: Transient RNA
silencing of tissue factor pathway inhibitor-2 modulates lung
cancer cell invasion. Clin Exp Metastasis. 26:457–467. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Safranek J, Pesta M, Holubec L, Kulda V,
Dreslerova J, Vrzalova J, Topolcan O, Pesek M, Finek J and Treska
V: Expression of MMP-7, MMP-9, TIMP-1 and TIMP-2 mRNA in lung
tissue of patients with non-small cell lung cancer (NSCLC) and
benign pulmonary disease. Anticancer Res. 29:2513–2517.
2009.PubMed/NCBI
|
|
11
|
Huang S, Chen J and Jia Y: Research on the
correlation of MMP9 and p53 expression with the prognosis of triple
negative breast cancer. Xiandai Shengwu Yixue Jinzhan. 14:881–884.
2014.
|
|
12
|
Choi JS, Baek HM, Kim S, Kim MJ, Youk JH,
Moon HJ, Kim EK and Nam YK: Magnetic resonance metabolic profiling
of breast cancer tissue obtained with core needle biopsy for
predicting pathologic response to neoadjuvant chemotherapy. PLoS
One. 8:e838662013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yari K and Rahimi Z, Moradi MT and Rahimi
Z: The MMP-2 −735 C allele is a risk factor for susceptibility to
breast cancer. Asian Pac J Cancer Prev. 15:6199–6203. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Fernandez-Garcia B, Eiró N, Marín L,
González-Reyes S, González LO, Lamelas ML and Vizoso FJ: Expression
and prognostic significance of fibronectin and matrix
metalloproteases in breast cancer metastasis. Histopathology.
64:512–522. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Li H, Huang J, Yang B, Xiang T, Yin X,
Peng W, Cheng W, Wan J, Luo F, Li H, et al: Mangiferin exerts
antitumor activity in breast cancer cells by regulating matrix
metalloproteinases, epithelial to mesenchymal transition, and
β-catenin signaling pathway. Toxicol Appl Pharmacol. 272:180–190.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Parsons SL, Watson SA, Collins HM, Griffin
NR, Clarke PA and Steele RJ: Gelatinase (MMP-2 and −9) expression
in gastrointestinal malignancy. Br J Cancer. 78:1495–1502. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Bucan V, Mandel K, Bertram C, Lazaridis A,
Reimers K, Park-Simon TW, Vogt PM and Hass R: LEF-1 regulates
proliferation and MMP-7 transcription in breast cancer cells. Genes
Cells. 17:559–567. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Katunina AI, Gershtein ES, Ermilova VD,
Tereshkina IV, Nazarenko AY, Tyleuova AA, Dvorova EK, Karabekova
ZK, Gritskevich MV and Berezov TT: Matrix metalloproteinases 2, 7,
and 9 in tumors and sera of patients with breast cancer. Bull Exp
Biol Med. 151:359–362. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Rahko E, Jukkola A, Melkko J, Paavo P,
Bloigu R, Talvensaari-Mattila A and Turpeenniemi-Hujanen T: Matrix
metalloproteinase-9 (MMP-9) immunoreactive protein has modest
prognostic value in locally advanced breast carcinoma patients
treated with an adjuvant antiestrogen therapy. Anticancer Res.
24:4247–4253. 2004.PubMed/NCBI
|
|
20
|
Li HC, Cao DC, Liu Y, Hou YF, Wu J, Lu JS,
Di GH, Liu G, Li FM, Ou ZL, et al: Prognostic value of matrix
metalloproteinases (MMP-2 and MMP-9) in patients with lymph
node-negative breast carcinoma. Breast Cancer Res Treat. 88:75–85.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Jones JL, Glynn P and Walker RA:
Expression of MMP-2 and MMP-9, their inhibitors, and the activator
MT1-MMP in primary breast carcinomas. J Pathol. 189:161–168. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lebeau A, Müller-Aufdemkamp C, Allmacher
C, Sauer U, Nerlich A, Lichtinghagen R and Löhrs U: Cellular
protein and mRNA expression patterns of matrix
metalloproteinases-2, −3 and −9 in human breast cancer: Correlation
with tumour growth. J Mol Histol. 35:443–455. 2004. View Article : Google Scholar : PubMed/NCBI
|
